Reports N Markets

REQUEST SAMPLE

Personalized Cancer Vaccine Market Size And Forecast

Error in rephrasing: [WinError 10061] No connection could be made because the target machine actively refused it

Global Personalized Cancer Vaccine Market Definition

Error in rephrasing: [WinError 10061] No connection could be made because the target machine actively refused it

What's inside a TRI industry report?

Error in rephrasing: [WinError 10061] No connection could be made because the target machine actively refused it

Global Personalized Cancer Vaccine Market Overview

Error in rephrasing: [WinError 10061] No connection could be made because the target machine actively refused it

Global Personalized Cancer Vaccine Market: Segmentation Analysis

Error in rephrasing: [WinError 10061] No connection could be made because the target machine actively refused it

Personalized Cancer Vaccine Market, By Cancer Type

Error in rephrasing: [WinError 10061] No connection could be made because the target machine actively refused it

Personalized Cancer Vaccine Market, By Mechanism Of Action Type

Error in rephrasing: [WinError 10061] No connection could be made because the target machine actively refused it

Personalized Cancer Vaccine Market, By Technology

Error in rephrasing: [WinError 10061] No connection could be made because the target machine actively refused it

Personalized Cancer Vaccine Market, By End-User

Error in rephrasing: [WinError 10061] No connection could be made because the target machine actively refused it

Personalized Cancer Vaccine Market, By Geography

Error in rephrasing: [WinError 10061] No connection could be made because the target machine actively refused it

Key Players

Error in rephrasing: [WinError 10061] No connection could be made because the target machine actively refused it

Company Market Ranking Analysis

Error in rephrasing: [WinError 10061] No connection could be made because the target machine actively refused it

Company Regional/Industry Footprint

Error in rephrasing: [WinError 10061] No connection could be made because the target machine actively refused it

Ace Matrix

Error in rephrasing: [WinError 10061] No connection could be made because the target machine actively refused it

Report Scope

Error in rephrasing: [WinError 10061] No connection could be made because the target machine actively refused it

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors. • Provision of market value (USD Billion) data for each segment and sub-segment. • Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market. • Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region. • Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled. • Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players • The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions. • Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis. • Provides insight into the market through Value Chain. • Market dynamics scenario, along with growth opportunities of the market in the years to come. • 6-month post-sales analyst support.

Error in rephrasing: [WinError 10061] No connection could be made because the target machine actively refused it

Frequently Asked Questions

What is the projected market size & growth rate of the Personalized Cancer Vaccine Market?

What are the key driving factors for the growth of the Personalized Cancer Vaccine Market?

What are the top players operating in the Personalized Cancer Vaccine Market?

What segments are covered in the Personalized Cancer Vaccine Market report?

How can I get a sample report/company profiles for the Personalized Cancer Vaccine Market?

Frequently Asked Questions About This Report

1What is the projected market size & growth rate of the Personalized Cancer Vaccine Market?

Personalized Cancer Vaccine Market was valued at USD 103,499.50 Thousand in 2023 and is projected to reach USD 576,147.10 Thousand by 2031, growing at a CAGR of 27.79% from 2024 to 2031.

2What are the key driving factors for the growth of the Personalized Cancer Vaccine Market?

The growing knowledge of genetic and molecular cancer has made it easier to identify particular tumor antigens and genetic mutations, which allows us to design personalized vaccines that aim for these unique markers.

3What are the top players operating in the Personalized Cancer Vaccine Market?

The major players are Moderna Inc., Gritstone Bio, Personalis Inc., Immatics N.V., CureVac N.V., Celldex Therapeutics, BioNTech SE.

4What segments are covered in the Personalized Cancer Vaccine Market report?

The Global Personalized Cancer Vaccine Market is Segmented on the basis of Cancer Type, Mechanism Of Action Type, Technology, End-User, and Geography.

5How can I get a sample report/company profiles for the Personalized Cancer Vaccine Market?

The sample report for the Personalized Cancer Vaccine Market can be obtained on demand from the website. Also, the 24*7 chat support & direct call services are provided to procure the sample report.


1 INTRODUCTION

1.1 MARKET DEFINITION

1.2 MARKET SEGMENTATION

1.3 RESEARCH TIMELINES

1.4 ASSUMPTIONS

1.5 LIMITATIONS
2 RESEARCH METHODOLOGY

2.1 DATA MINING

2.1.1 SECONDARY RESEARCH

2.1.2 PRIMARY RESEARCH

2.1.3 SUBJECT MATTER EXPERT ADVICE

2.1.4 QUALITY CHECK

2.1.5 FINAL REVIEW

2.2 DATA TRIANGULATION

2.3 BOTTOM-UP APPROACH

2.4 TOP-DOWN APPROACH

2.5 RESEARCH FLOW

2.6 DATA SOURCES
3 EXECUTIVE SUMMARY

3.1 GLOBAL PERSONALIZED CANCER VACCINE MARKET OVERVIEW

3.2 GLOBAL PERSONALIZED CANCER VACCINE MARKET ESTIMATES AND FORECAST (USD THOUSAND), 2022-2031

3.3 GLOBAL PERSONALIZED CANCER VACCINE MARKET ECOLOGY MAPPING

3.4 GLOBAL PERSONALIZED CANCER VACCINE MARKET ABSOLUTE MARKET OPPORTUNITY

3.5 GLOBAL PERSONALIZED CANCER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY REGION

3.6 GLOBAL PERSONALIZED CANCER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY CANCER TYPE

3.7 GLOBAL PERSONALIZED CANCER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY MECHANISM OF ACTION TYPE

3.8 GLOBAL PERSONALIZED CANCER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY TECHNOLOGY

3.9 GLOBAL PERSONALIZED CANCER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY END-USER

3.10 GLOBAL PERSONALIZED CANCER VACCINE MARKET GEOGRAPHICAL ANALYSIS (CAGR %)

3.11 GLOBAL PERSONALIZED CANCER VACCINE MARKET, BY CANCER TYPE (USD THOUSAND)

3.12 GLOBAL PERSONALIZED CANCER VACCINE MARKET, BY MECHANISM OF ACTION TYPE (USD THOUSAND)

3.13 GLOBAL PERSONALIZED CANCER VACCINE MARKET, BY TECHNOLOGY (USD THOUSAND)

3.14 GLOBAL PERSONALIZED CANCER VACCINE MARKET, BY END-USER (USD THOUSAND)

3.15 FUTURE MARKET OPPORTUNITIES

3.16 PRODUCT LIFELINE
4 MARKET OUTLOOK

4.1 GLOBAL PERSONALIZED CANCER VACCINE MARKET EVOLUTION

4.2 GLOBAL PERSONALIZED CANCER VACCINE MARKET OUTLOOK
4.3 MARKET DRIVERS

4.3.1 THE GROWING KNOWLEDGE OF GENETIC AND MOLECULAR CANCER HAS MADE IT EASIER TO IDENTIFY PARTICULAR TUMOR ANTIGENS AND GENETIC MUTATIONS, WHICH ALLOWS US TO DESIGN PERSONALIZED VACCINES THAT AIM FOR THESE UNIQUE MARKERS

4.3.2 MORE TARGETED AND EFFECTIVE TREATMENT OPTIONS ARE NEEDED AS THE GLOBAL CANCER BURDEN KEEPS RISING. PERSONALIZED CANCER VACCINES PROVIDE A HOPEFUL WAY TO TACKLE THE INDIVIDUAL AND CHANGING NATURE OF CANCER
4.4 MARKET RESTRAINTS

4.4.1 PERSONALIZED CANCER VACCINES ARE BY NATURE COMPLEX TO MANUFACTURE, NEEDING TO BE CUSTOMIZED TO FIT THE INDIVIDUAL TUMOR PROFILE OF EACH PATIENT. THIS MAY REQUIRE A LOT OF TIME AND MONEY.

4.4.2 MARKET GROWTH IS ANTICIPATED TO BE IMPEDED BY THE HIGH COST ASSOCIATED WITH PRODUCT MANUFACTURING
4.5 MARKET OPPORTUNITY

4.5.1 WITH MINIMUM OFF-TARGET EFFECTS, PERSONALIZED CANCER VACCINES MAY BE ABLE TO PROVIDE HIGHLY TARGETED TREATMENTS, WHICH MAY IMPROVE PATIENT OUTCOMES AND REDUCE SIDE EFFECTS

4.5.2 INCREASING MARKET PLAYERS' COOPERATION, MERGERS, AND ACQUISITIONS WOULD PROLONG THEIR PROFITABLE OPPORTUNITIES
4.6 MARKET TRENDS

4.6.1 TECHNOLOGICAL DEVELOPMENTS IN GENOMIC PROFILING AND BIOINFORMATICS ARE THE DRIVING FORCE BEHIND THE MARKET'S EXPANSION
4.7 PORTER’S FIVE FORCES ANALYSIS

4.7.1 THREAT OF NEW ENTRANTS

4.7.2 THREAT OF SUBSTITUTES

4.7.3 BARGAINING POWER OF SUPPLIERS

4.7.4 BARGAINING POWER OF BUYERS

4.7.5 INTENSITY OF COMPETITIVE RIVALRY
4.8 VALUE CHAIN ANALYSIS
4.9 PRICING ANALYSIS
4.10 MACROECONOMIC ANALYSIS
5 MARKET, BY CANCER TYPE

5.1 OVERVIEW

5.2 GLOBAL PERSONALIZED CANCER VACCINE MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY CANCER TYPE

5.3 LUNG CANCER

5.4 BREAST CANCER

5.5 COLORECTAL CANCER

5.6 LEUKAEMIA

5.7 PROSTATE CANCER
6 MARKET, BY MECHANISM OF ACTION TYPE

6.1 OVERVIEW

6.2 GLOBAL PERSONALIZED CANCER VACCINE MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY MECHANISM OF ACTION TYPE

6.3 TUMOUR-ASSOCIATED ANTIGENS (TAAS)

6.4 TUMOUR-SPECIFIC ANTIGENS (TSAS)

6.5 SOMATIC MUTATIONS IN CANCER PHARMACOGENOMICS

6.6 PHARMACOGENOMICS TOWARDS GENOMIC POLYMORPHISM
7 MARKET, BY TECHNOLOGY

7.1 OVERVIEW

7.2 GLOBAL PERSONALIZED CANCER VACCINE MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY TECHNOLOGY

7.3 DENDRITIC CELLS (DC) CANCER VACCINES

7.4 RECOMBINANT CANCER VACCINES

7.5 ANTIGEN/ADJUVANT CANCER VACCINES

7.6 VIRAL VECTOR AND DNA CANCER VACCINES
8 MARKET, BY END-USER

8.1 OVERVIEW

8.2 GLOBAL PERSONALIZED CANCER VACCINE MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY END-USER

8.3 HOSPITALS

8.4 HOMECARE

8.5 SPECIALTY CLINICS

8.6 OTHERS
9 MARKET, BY GEOGRAPHY

9.1 OVERVIEW

9.2 NORTH AMERICA

9.2.1 NORTH AMERICA MARKET SNAPSHOT

9.2.2 U.S.

9.2.3 CANADA

9.2.4 MEXICO

9.3 EUROPE

9.3.1 EUROPE MARKET SNAPSHOT

9.3.2 GERMANY

9.3.3 FRANCE

9.3.4 UK

9.3.5 ITALY

9.3.6 SPAIN

9.3.7 REST OF EUROPE

9.4 ASIA PACIFIC

9.4.1 ASIA PACIFIC MARKET SNAPSHOT

9.4.2 CHINA

9.4.3 JAPAN

9.4.4 INDIA

9.4.5 REST OF ASIA PACIFIC

9.5 LATIN AMERICA

9.5.1 LATIN AMERICA MARKET SNAPSHOT

9.5.2 BRAZIL

9.5.3 ARGENTINA

9.5.4 REST OF LATIN AMERICA

9.6 MIDDLE EAST AND AFRICA

9.6.1 MIDDLE EAST AND AFRICA MARKET SNAPSHOT

9.6.2 UAE

9.6.3 SAUDI ARABIA

9.6.4 SOUTH AFRICA

9.6.5 REST OF MIDDLE EAST AND AFRICA
10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW

10.2 COMPANY MARKET RANKING ANALYSIS

10.3 REGIONAL FOOTPRINT

10.4 COMPANY INDUSTRY FOOTPRINT

10.5 ACE MATRIX

10.5.1 ACTIVE

10.5.2 CUTTING EDGE

10.5.3 EMERGING

10.5.4 INNOVATORS
11 COMPANY PROFILES
11.1 MODERNA, INC.

11.1.1 COMPANY OVERVIEW

11.1.2 COMPANY INSIGHTS

11.1.3 BUSINESS BREAKDOWN

11.1.4 PRODUCT BENCHMARKING

11.1.5 KEY DEVELOPMENTS
11.2 GRITSTONE BIO

11.2.1 COMPANY OVERVIEW

11.2.2 COMPANY INSIGHTS

11.2.3 PRODUCT BENCHMARKING
11.3 PERSONALIS INC.

11.3.1 COMPANY OVERVIEW

11.3.2 COMPANY INSIGHTS

11.3.1 BUSINESS BREAKDOWN

11.3.2 PRODUCT BENCHMARKING

11.3.3 KEY DEVELOPMENTS
11.4 CUREVAC N.V.

11.4.1 COMPANY OVERVIEW

11.4.2 COMPANY INSIGHTS

11.4.3 PRODUCT BENCHMARKING

11.4.4 KEY DEVELOPMENTS
11.5 CELLDEX THERAPEUTICS

11.5.1 COMPANY OVERVIEW

11.5.2 COMPANY INSIGHTS

11.5.3 PRODUCT BENCHMARKING
11.6 BIONTECH SE

11.6.1 COMPANY OVERVIEW

11.6.2 COMPANY INSIGHTS

11.6.3 PRODUCT BENCHMARKING

11.6.4 KEY DEVELOPMENTS

11.6.5 WINNING IMPERATIVES

11.6.6 CURRENT FOCUS & STRATEGIES

11.6.7 THREAT FROM COMPETITION

11.6.8 SWOT ANALYSIS
11.7 AYALA PHARMACEUTICALS, INC. (ADVAXIS)

11.7.1 COMPANY OVERVIEW

11.7.2 COMPANY INSIGHTS

11.7.3 PRODUCT BENCHMARKING

11.7.4 KEY DEVELOPMENTS
11.8 F. HOFFMANN-LA ROCHE LTD

11.8.1 COMPANY OVERVIEW

11.8.2 COMPANY INSIGHTS

11.8.3 BUSINESS BREAKDOWN

11.8.4 PRODUCT BENCHMARKING

11.8.5 KEY DEVELOPMENTS

11.8.6 WINNING IMPERATIVES

11.8.7 CURRENT FOCUS & STRATEGIES

11.8.8 THREAT FROM COMPETITION

11.8.9 SWOT ANALYSIS
11.9 IMMATICS N.V.

11.9.1 COMPANY OVERVIEW

11.9.2 COMPANY INSIGHTS

11.9.3 PRODUCT BENCHMARKING

11.9.4 KEY DEVELOPMENTS

11.9.5 WINNING IMPERATIVES

11.9.6 CURRENT FOCUS & STRATEGIES

11.9.7 THREAT FROM COMPETITION

11.9.8 SWOT ANALYSIS

The research starts with the extensive procurement process of data/information and statistics from company annual reports, government websites, statistics agencies, and paid databases. This information creates a base for the study. The information also helps to define the scope and to narrow down the area for study for the market. This raw information is processed and analyzed to extract crisp data points which currently affect or are likely to affect the industry during the forecast period. After analyzing the information, a proprietary statistical tool is used for market estimation and forecast, which generates the quantitative figures of the market/sub-segments in the current scenario as well as for the forecast period. After estimating the markets and estimates, the numbers are verified with industry participants and key opinion leaders. The wide network of industry participants add value to the research and verify the numbers and estimates provided in the study. At the last stage of the research process, a final report is prepared, which is then published on different websites as well as distributed through various channels. The below figure contains the different stages of the research process to produce the report.

1.1 DATA MINING

Data mining is an extensive part of our research process. It involves the procurement of market data and related information from different verified and credible sources. This step helps to obtain raw information about the industry and their Drivetrain, the monetary process for different end uses, the pool of market participants, and the nature of the industry and scope of the study. The data mining stage comprises both primary and secondary sources of information.

1.2 SECONDARY RESEARCH

In the secondary research process, various sources are used to identify and gather industry trends and information for the research process. We at TRI have access to some of the most diversified and extensive paid databases, which give us the most accurate data/information on markets Customers, and pricing. Mentioned below is a detailed list of sources that have been used for this study. Please note that this list is not limited to the names as mentioned; we also access other data sources depending on the need.

1.3 PRIMARY RESEARCH

In the primary research process, in-depth primary interviews are conducted with the CXOs to understand the market share, customer base, pricing strategies, channel partners, and other necessary information. Besides, in-depth primary interviews are conducted with the CXOs of vendors, channel partners, and others to validate the supply-side information. In addition, various key industry participants from both the supply and demand side are interviewed to obtain qualitative and quantitative information on the market. In-depth interviews with key primary respondents, including industry professionals, subject matter experts (Corporates), industry consultants, and C-Component executives of major companies, are conducted to obtain critical qualitative and quantitative information pertaining to the market, as well as to assess the prospects for market growth during the forecast period. Detailed information on these primary respondents is mentioned below.

1.4 FORCASTING TECHNIQUES

We at Markstats Research Insights Private Limited follow an extensive process for arriving at market estimations, which involves the use of multiple forecasting techniques as mentioned below.